Saturday, November 18, 2017 11:08:20 AM
November 15, 2017
Initiating Coverage: Resverlogix Corp. (RVX-T)
The New Doctor Is In. First Prescription Is A Full Dose of Resverlogix: C$8.55
12 Month Target: $8.55
Rating: BUY
CLICK HERE TO VIEW FULL REPORT
<C2928E8CA48E48F2B7401720B6478104.png>
The Canadian biotechnology sector is primed for a big turnaround. As Beacon's new analyst, I have had the opportunity to conduct a thorough environmental scan of the industry, and have created a "watch-list" of undervalued Canadian companies, whose science is innovative, coupled with impressive market potential and stellar management teams.
Epigenetics and Bromodomain Extra-Terminal (BET) inhibition are among the hottest fields in the global biotechnology sector with significant upside potential. Epigenetics is the field of medicine where the re-engineering of the environment impacts the final genetic product. When BET inhibition targets the right proteins in a diseased state, this has dramatic impact for affected patients, their Quality of Life, and life span.
Resverlogix Corp. has developed a proprietary platform to address epigenetics and BET inhibition in cardiovascular disease (CVD), chronic kidney disease (CKD), as well as orphan diseases impacted by Complement biology.
After taking a deep dive in Canadian biotech, we have concluded that Resverlogix may be one of the most undervalued biotech companies in Canada.
We are initiating coverage of Resverlogix with a Buy rating and C$8.55 target price based on the risk-adjusted NPV of its two initial disease states, CVD & CKD.
<C2928E8CA48E48F2B7401720B6478104.png>
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM